Shield Therapeutics PLC banner

Shield Therapeutics PLC
LSE:STX

Watchlist Manager
Shield Therapeutics PLC Logo
Shield Therapeutics PLC
LSE:STX
Watchlist
Price: 8.1 GBX 0.62% Market Closed
Market Cap: £86.5m

Wall Street
Price Targets

STX Price Targets Summary
Shield Therapeutics PLC

Wall Street analysts forecast STX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STX is 17.68 GBX with a low forecast of 14.14 GBX and a high forecast of 24.15 GBX.

Lowest
Price Target
14.14 GBX
75% Upside
Average
Price Target
17.68 GBX
118% Upside
Highest
Price Target
24.15 GBX
198% Upside
Shield Therapeutics PLC Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-28%
Average Miss
N/A
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-28%
Average Miss

The compound annual growth rate of Shield Therapeutics PLC's revenue for the next 4 years is 38%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STX's stock price target?
Price Target
17.68 GBX

According to Wall Street analysts, the average 1-year price target for STX is 17.68 GBX with a low forecast of 14.14 GBX and a high forecast of 24.15 GBX.

What is Shield Therapeutics PLC's Revenue forecast?
Projected CAGR
38%

The compound annual growth rate of Shield Therapeutics PLC's revenue for the next 4 years is 38%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett